Fda allocated $3.9 million to study the impact of taste
Date:2023-07-17 11:05:25 Classification
:【Statute】 Visits:
In the United States, the Food and Drug Administration of the Comprehensive Cancer Center of Ohio State University recently provided a subsidy of 3.9 million dollars to the Tobacco Research Center to assess the impact of e-cigarette taste on smoking behavior of current adult smokers.
This study will be co led by Theodore Wagner, director of the Ohio Tobacco Research Center, and Tracy Smith of the Cancer Center at Hollins Medical University in South Carolina.
Wagner said, "The FDA must decide how to balance its goal of protecting young people and providing harm reduction options to adults. This new experiment will produce important data to help make more informed public health decisions with lasting impact
Wagner said, "Currently, the FDA is making regulatory decisions on the taste of e-cigarettes, but the scientific data is incomplete "Existing data shows that smokers also prefer scented Electronic cigarette. Although some research shows that scented Electronic cigarette may be more conducive to the conversion to VPIN, these studies are not strict enough for FDA to make a decision according to its regulatory decisions. Our research will be the first to provide FDA with clear information about the benefits of e-cigarette flavors for adult smokers."
This national Randomized controlled trial will recruit as many as 1.500 smokers from all over the country. The researchers will measure the impact of the taste of electronic cigarettes on the absorption and attractiveness of products, desire for cigarettes, symptoms, dependence and smoking behavior. Comprehensive nicotine replacement therapy will be used as a comparison to determine the potential added benefits of e-cigarettes and nicotine replacement therapy.
Wagner said, "If our research shows no significant improvement in the use of switch flavored e-cigarettes, continuing to sell these products may not be tenable; however, if there is a significant improvement in the situation, these findings will play an important balancing role in current FDA regulations and help with future decisions.